JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JVI Accepts, published online ahead of print on 7 February 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.01620-06v1
81/9/4540    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perez-Bercoff, D.
Right arrow Articles by Clavel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perez-Bercoff, D.
Right arrow Articles by Clavel, F.
J. Virol. doi:10.1128/JVI.01620-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RESISTANCE TO NUCLEOSIDE ANALOGUES AND REPLICATIVE CAPACITY IN PRIMARY HUMAN MACROPHAGES

Danielle Perez-Bercoff, Sébastien Wurtzer, Séverine Compain, Henri Benech, and François Clavel*

Unité de Rercherche Antivirale, Inserm U552, Paris F-75018 France; Université Denis Diderot Paris 7, Paris F-75018 France.; Service de Pharmacologie et d'Immunologie DSV/DRM, CEA/Saclay, 91191 Gif sur Yvette cedex, France

* To whom correspondence should be addressed. Email: clavel{at}bichat.inserm.fr.


   Abstract

Antiretroviral treatment failure is associated with the emergence of resistant HIV-1 populations which often express altered replicative capacity (RC). Resistance and replicative capacity (RC) of clinical HIV-1 strains, however, are generally assayed using activated PBMCs or tumor cell lines. Because of their high proliferation rate and concurrent high dNTP content, both resistance and RC alterations might be misestimated in these cell systems. We have evaluated resistance of HIV-1 clones expressing a variety of RT resistance mutations in primary human macrophages using a single cycle system. Our experiments indicate that d4T, ddI and 3TC are more potent in macrophages than in HeLa-derived P4 tumor cells. Mutant viruses bearing thymidine analogue mutations (TAMs) or the K65R mutation had similar resistance levels in the two cell types. Strikingly, however, the M184V mutant, although fully resistant to 3TC in P4 cells, maintained some susceptibility to 3TC in macrophages from 8 out of 11 donors. Using the same system, the impact of resistance mutations on HIV RC was minimal in activated PBMCs and in P4 cells. By contrast, mutant viruses exhibited strongly impaired RC relative to WT in macrophages, with the following RC order: WT > 2TAMs > 4TAMs = M184V > K65R. In undifferentiated monocytes, WT virus replication could be detected in 3 of 6 donors, but replication of all mutant viruses remained undetectable. Altogether our results confirm that NRTIs are powerful antiviral agents in differentiated macrophages, reveal that HIV resistance to some NRTIs may be less efficient in these cells and indicate that resistance-associated loss of RC is more pronounced in macrophages than in high-dNTP content cell systems.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.